Paul D. Rubin is a partner based in the Washington, D.C. office and is the Co-Chair of the firm’s Healthcare & Life Sciences Group and the Chair of the FDA Regulatory practice. His practice focuses on FDA/FTC regulatory matters. Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues ranging from strategic regulatory counseling to complex compliance and enforcement matters - including the representation of companies and individuals under investigation by FDA’s Office of Criminal Investigations (OCI). He also routinely conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions.